Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (8796)
All Articles published online
|
Publishing Process of This Article
|
May 6, 2017 (publication date) through Apr 19, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastrointestinal Pharmacology and Therapeutics
ISSN
2150-5349
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Sultan KS, Berkowitz JC, Khan S. Combination therapy for inflammatory bowel disease. World J Gastrointest Pharmacol Ther 2017; 8(2): 103-113 [PMID: 28533919 DOI: 10.4292/wjgpt.v8.i2.103] |
|---|---|
| URL: | https://www.wjgnet.com/2150-5349/full/v8/i2/103.htm |
| Number | Citing Articles |
| 1 |
Ian Edwin Cock. Is the pharmaceutical industry’s preoccupation with the monotherapy drug model stifling the development of effective new drug therapies?. Inflammopharmacology 2018; 26(3): 861 doi: 10.1007/s10787-018-0488-7
|
| 2 |
Laura M. Jacobsen, Brittney N. Newby, Daniel J. Perry, Amanda L. Posgai, Michael J. Haller, Todd M. Brusko. Immune Mechanisms and Pathways Targeted in Type 1 Diabetes. Current Diabetes Reports 2018; 18(10) doi: 10.1007/s11892-018-1066-5
|
| 3 |
Arshdeep Singh, Ramit Mahajan, Saurabh Kedia, Amit Kumar Dutta, Abhinav Anand, Charles N. Bernstein, Devendra Desai, C. Ganesh Pai, Govind Makharia, Harsh Vardhan Tevethia, Joyce WY Mak, Kirandeep Kaur, Kiran Peddi, Mukesh Kumar Ranjan, Perttu Arkkila, Rakesh Kochhar, Rupa Banerjee, Saroj Kant Sinha, Siew Chien Ng, Stephen Hanauer, Suhang Verma, Usha Dutta, Vandana Midha, Varun Mehta, Vineet Ahuja, Ajit Sood. Use of thiopurines in inflammatory bowel disease: an update. Intestinal Research 2022; 20(1): 11 doi: 10.5217/ir.2020.00155
|
| 4 |
Fernando Magro, Gonçalo Cordeiro, Andreia Martins Dias, Maria Manuela Estevinho. Inflammatory Bowel Disease – Non-biological treatment. Pharmacological Research 2020; 160: 105075 doi: 10.1016/j.phrs.2020.105075
|
| 5 |
Daniel Schaffert, Igor Bibi, Mara Blauth, Christian Lull, Jan Alwin von Ahnen, Georg Groß, Theresa Schulze-Hagen, Johannes Knitza, Sebastian Kuhn, Johannes Benecke, Astrid Schmieder, Jan Leipe, Victor Olsavszky. Automated Machine Learning Predicts Necessary Upcoming Therapy Changes in Patients With Psoriasis Vulgaris et Arthritis And Uncovers New Influences On Disease Progression: Retrospective Study (Preprint). JMIR Formative Research 2023; doi: 10.2196/55855
|
| 6 |
Sheng Zhang Lim, Eng Wee Chua. Revisiting the Role of Thiopurines in Inflammatory Bowel Disease Through Pharmacogenomics and Use of Novel Methods for Therapeutic Drug Monitoring. Frontiers in Pharmacology 2018; 9 doi: 10.3389/fphar.2018.01107
|
| 7 |
Stephanie Gold, Louis Cohen. Pediatric Inflammatory Bowel Disease. 2023; : 423 doi: 10.1007/978-3-031-14744-9_32
|
| 8 |
Yating Niu, Jun Zhang, Dianhua Shi, Weibiao Zang, Jianguo Niu. Glycosides as Potential Medicinal Components for Ulcerative Colitis: A Review. Molecules 2023; 28(13): 5210 doi: 10.3390/molecules28135210
|
| 9 |
Marisa Iborra, Julia Herreras, Marta Maia Boscá-Watts, Xavier Cortés, Galo Trejo, Elena Cerrillo, David Hervás, Miguel Mínguez, Belén Beltrán, Pilar Nos. Withdrawal of Azathioprine in Inflammatory Bowel Disease Patients Who Sustain Remission: New Risk Factors for Relapse. Digestive Diseases and Sciences 2019; 64(6): 1612 doi: 10.1007/s10620-018-5429-1
|
| 10 |
Waseem Ahmed, Jonathan Galati, Anand Kumar, Paul J. Christos, Randy Longman, Dana J. Lukin, Ellen Scherl, Robert Battat. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology 2022; 20(3): e361 doi: 10.1016/j.cgh.2021.03.034
|
| 11 |
Supriya Roy, Suneela Dhaneshwar, Tarique Mahmood, Swatantra Kumar, Shailendra K. Saxena. Pre-clinical investigation of protective effect of nutraceutical D-glucosamine on TNBS-induced colitis. Immunopharmacology and Immunotoxicology 2023; 45(2): 172 doi: 10.1080/08923973.2022.2128370
|
| 12 |
Aliakbar Yousefi‐Ahmadipour, Amir Rashidian, Mohammad Reza Mirzaei, Alireza Farsinejad, Fatemeh PourMohammadi‐Nejad, Mahmoud Ghazi‐Khansari, Jafar Ai, Sadegh Shirian, Amir Allahverdi, Jamileh Saremi, Somayeh Ebrahimi‐Barough. Combination therapy of mesenchymal stromal cells and sulfasalazine attenuates trinitrobenzene sulfonic acid induced colitis in the rat: The S1P pathway. Journal of Cellular Physiology 2019; 234(7): 11078 doi: 10.1002/jcp.27944
|
| 13 |
Taku Kobayashi, Eri Udagawa, Akihito Uda, Toshifumi Hibi, Tadakazu Hisamatsu. Impact of immunomodulator use on treatment persistence in patients with ulcerative colitis: A claims database analysis. Journal of Gastroenterology and Hepatology 2020; 35(2): 225 doi: 10.1111/jgh.14825
|
| 14 |
Shinsuke Kumei, Toshihiro Sakurai, Suketo So, Soichi Itaba, Hirotada Akiho, Shigeo Nakamura, Hyonji Kim, Masahiro Yamasaki, Noritaka Takatsu, Ryuichiro Maekawa, Ryosuke Sakemi, Tatsuyuki Watanabe, Michihiko Shibata, Keiichiro Kume, Ichiro Yoshikawa, Yasuhiro Takaki, Masaru Harada. Impact of the Concomitant Use of Immunomodulator and a Lower Week 8 Partial Mayo Score on the Persistence of Adalimumab in Refractory Ulcerative Colitis. Internal Medicine 2021; 60(24): 3849 doi: 10.2169/internalmedicine.7279-21
|
| 15 |
Milan Buc. Current and prospective biologics and small molecules in the treatment of inflammatory bowel diseases. Vnitřní lékařství 2018; 64(3): 280 doi: 10.36290/vnl.2018.039
|
| 16 |
Seong Ji Choi, Min Sun Kim, Eun Sun Kim, Juneyoung Lee, Jae Min Lee, Hyuk Soon Choi, Bora Keum, Yoon Tae Jeen, Hong Sik Lee, Hoon Jai Chun, Chang Duck Kim. Higher risk of tuberculosis in combination therapy for inflammatory bowel disease. Medicine 2020; 99(44): e22897 doi: 10.1097/MD.0000000000022897
|
| 17 |
Chinmay M. Jogdeo, Sudipta Panja, Shrey Kanvinde, Ekta Kapoor, Kasturi Siddhanta, David Oupický. Advances in Lipid‐Based Codelivery Systems for Cancer and Inflammatory Diseases. Advanced Healthcare Materials 2023; 12(7) doi: 10.1002/adhm.202202400
|
| 18 |
Mahnur Haider, Bret Lashner. Dual Targeted Therapy for the Management of Inflammatory Bowel Disease. Journal of Clinical Gastroenterology 2021; 55(8): 661 doi: 10.1097/MCG.0000000000001583
|
| 19 |
Kristina Lampič, Jurij Trontelj, Helena Prosen, David Drobne, Alenka Šmid, Tomaž Vovk. Determination of 6-thioguanine and 6-methylmercaptopurine in dried blood spots using liquid chromatography-tandem mass spectrometry: Method development, validation and clinical application. Clinica Chimica Acta 2019; 499: 24 doi: 10.1016/j.cca.2019.08.024
|
| 20 |
Shikha Nayar, Judy H. Cho. From single-target to cellular niche targeting in Crohn's disease: intercepting bad communications. eBioMedicine 2021; 74: 103690 doi: 10.1016/j.ebiom.2021.103690
|
| 21 |
Abhinav Vasudevan, Ajay Raghunath, Shane Anthony, Cian Scanlon, Miles P. Sparrow, Peter R. Gibson, Daniel R. van Langenberg. Higher Mucosal Healing with Tumor Necrosis Factor Inhibitors in Combination with Thiopurines Compared to Methotrexate in Crohn’s Disease. Digestive Diseases and Sciences 2019; 64(6): 1622 doi: 10.1007/s10620-018-5422-8
|
| 22 |
Keith Sultan, Noah Becher. Inflammatory Bowel Disease. Clinical Gastroenterology 2021; : 61 doi: 10.1007/978-3-030-81780-0_3
|
| 23 |
瑞芳 胡. Clinical Research Progress of Infliximab Combined with Azathioprine in the Treatment of Inflammatory Bowel Disease. Advances in Clinical Medicine 2022; 12(12): 10987 doi: 10.12677/ACM.2022.12121582
|